2026-04-14T05:06:55Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/115452025-10-24T10:41:47Zcom_2072_378070com_2072_378040col_2072_378092

Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis Szaflarski, Jerzy Besson, Hervé Klein, Pavel JAVIER, SALAS-PUIG D'Souza, Wendyl Faught, Edward Institut Català de la Salut [Szafarski JP] University of Alabama at Birmingham (UAB) Heersink School of Medicine Department of Neurology and UAB Epilepsy Center, Birmingham, AL, USA. [Besson H] UCB Pharma, Breda, Netherlands. [D’Souza W] Department of Medicine, St Vincent’s Hospital Melbourne, The University of Melbourne, Melbourne, VIC, Australia. [Faught E] Emory Epilepsy Center, Atlanta, GA, USA. [Klein P] Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA. [Reuber M] The University of Shefeld, Shefeld, UK. [Salas Puig J] Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Avaluació de resultats (Assistència sanitària) Epilèpsia - Tractament Anticonvulsius - Ús terapèutic ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Epilepsy Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Central Nervous System Agents::Anticonvulsants Other subheadings::Other subheadings::/therapeutic use TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::epilepsia Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos del sistema nervioso central::anticonvulsivantes Otros calificadores::Otros calificadores::/uso terapéutico Comorbidity; Effectiveness; Tolerability Comorbilitat; Eficàcia; Tolerabilitat Comorbilidad; Eficacia; Tolerabilidad Objective To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. Methods EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor−related epilepsy [BTRE], and traumatic brain injury−related epilepsy [TBIE]). Results At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively. Conclusions BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE. 2024-06-04T10:58:02Z 2024-06-04T10:58:02Z 2024-06 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Szaflarski JP, Besson H, D'Souza W, Faught E, Klein P, Reuber M, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol. 2024 Jun;271:3169–3185. 1432-1459 https://hdl.handle.net/11351/11545 10.1007/s00415-024-12253-z 38436680 001175862900001 http://hdl.handle.net/11351/11545 eng Journal of Neurology;271 https://doi.org/10.1007/s00415-024-12253-z This study was funded by UCB Pharma. Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Springer Scientia